Ispire's Q3 earnings report reveals massive growth

May.17.2023
Ispire's Q3 earnings report reveals massive growth
Ispire released Q3 2023 financial report with impressive YoY revenue growth of 26.9% and gross profit growth of 51.9%.

On May 16th, Ispire announced the release of their financial report for the third quarter of 2023, ending on March 31st. The company also submitted their 10-Q quarterly report to the US Securities and Exchange Commission (SEC) on May 15th. According to the report, Ispire saw a year-over-year revenue growth of 26.9%, reaching $24.1 million in the third quarter, while their gross profit increased by 51.9% to $4.5 million.


It's worth noting that the company's fiscal year end is on June 30, 2023, and they have not chosen December 31 as their fiscal year end date.


Rise in Cannabis Smoking Accessories Sales is a Popular Betting Trend


Michael Wang, the Chief Financial Officer of Ispire, has stated that the company is expecting a continuous revenue growth of 58% to 98% in the fourth quarter of their marijuana smoking devices products.


He added:


We are focused on a multi-pronged strategy aimed at increasing sales of our electronic cigarette products and developing CBD vaporization products with an emphasis on medical and recreational use.


Third Quarter Performance: Tobacco vaporization remains the main product.


In the third quarter of 2023, Ispire recorded a year-on-year revenue growth of 26.9%, reaching $24.1 million. The revenue contribution of electronic cigarette products was $16.5 million, while that of CBD-related vaporizer products was $7.6 million. Gross profit grew 51.9% year-on-year to $4.5 million. However, total operating expenses increased by 106.2% YoY, reaching $8 million compared to $3.9 million in the same period of 2022. Net loss amounted to $3.1 million, whereas in the same period of 2022, the net loss was $1 million.


Looking ahead to the future.


Ispire has provided a projection for its CBD vaporization products for the fourth quarter of 2023 (ending June 30, 2023). The company began marketing CBD vaporization products in mid-2020, with revenue reaching $7.6 million in the third quarter of 2023. It is expected that the revenue in the fourth quarter of 2023 for CBD vaporization products will increase by 58% to 98% compared to the third quarter, with projected revenue ranging between $12 million to $15 million.


According to reports, Ispire is a company that specializes in research and development, design, commercialization, sales, promotion, and distribution of branded electronic cigarettes and CBD vaporization products. The company's tobacco electronic cigarette products are sold under the Aspire brand name.


References:


Ispire Technology Inc. has released its financial results for the third quarter of 2023.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s E-Cigarette Exports USD 1.096 billion in November, UK and South Korea Offset U.S. Decline
China’s e-cigarette exports edged lower in November 2025, totaling USD 1.096 billion, down 0.2% month-on-month, as a decline in shipments to the United States was partially offset by stronger demand from the United Kingdom, Germany and South Korea, according to data released by the General Administration of Customs of China.
Dec.22 by 2FIRSTS.ai
China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China Tobacco Annual Meeting Flags “New Growth Drivers” for 2026: Cigarette Innovation, Domestic Cigars, Overseas Business and Multi-Purpose Use
China’s tobacco authorities used their annual industry meeting in Beijing to outline new growth drivers for 2026, highlighting cigarette innovation, domestic cigars, overseas business expansion and multi-purpose tobacco applications.
Jan.20
Russia's Finance Ministry Proposes Regional Vape Sales Bans from 2026
Russia's Finance Ministry Proposes Regional Vape Sales Bans from 2026
Russian Finance Ministry has drafted amendments allowing regional governments to ban the retail sale of vapes and e-liquids between September 1, 2026, and September 1, 2031. Regions must enact their own legislation and notify the Federal Service for Alcohol and Tobacco Control (Rosalkogoltabakkontrol), which will publish a list of participating regions.
Dec.08 by 2FIRSTS.ai
New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
New Zealand Survey Finds Adult Daily Vaping Prevalence at 11.7%, Concentrated Among Youth and Disadvantaged Groups)
A survey report released by the Public Health Communication Centre Aotearoa shows that despite New Zealand implementing stricter vaping regulations in 2025, including a ban on disposable products and tighter flavour restrictions, daily vaping rates continue to rise. The research body urges close monitoring of behavioural changes following the new rules coming into force.
Dec.05 by 2FIRSTS.ai
Canada’s B.C. Passes First Vaping Cost-Recovery Framework, Allowing Government to Sue Manufacturers Over Health Expenses
Canada’s B.C. Passes First Vaping Cost-Recovery Framework, Allowing Government to Sue Manufacturers Over Health Expenses
According to the Nelson Star, British Columbia has passed the Vaping Product Damages and Health Care Costs Recovery Act by a 49–42 vote. The legislation enables the provincial government to seek recovery of future public health costs from vape manufacturers, following models used in opioid and tobacco litigation.
Dec.03
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
Vape Company Takes FDA to Court for Stalling Premarket Decision for Half a Decade
California-based vape manufacturer Schwartz E-Liquid (USA Vape Lab) has sued the U.S. Food and Drug Administration (FDA) in federal court, alleging the agency unlawfully failed to issue a decision on its premarket application for flavored e-cigarette products for more than five years. The company is seeking a court order compelling the FDA to act within 90 days.
Nov.26 by 2FIRSTS.ai